CN105456319A - Formula for treating inflammatory bowel disease - Google Patents
Formula for treating inflammatory bowel disease Download PDFInfo
- Publication number
- CN105456319A CN105456319A CN201510937154.8A CN201510937154A CN105456319A CN 105456319 A CN105456319 A CN 105456319A CN 201510937154 A CN201510937154 A CN 201510937154A CN 105456319 A CN105456319 A CN 105456319A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- formula
- intestinal
- inflammatory bowel
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 5
- 241000208340 Araliaceae Species 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004473 Threonine Substances 0.000 claims abstract description 12
- 235000018417 cysteine Nutrition 0.000 claims abstract description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 11
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 11
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 11
- 239000011648 beta-carotene Substances 0.000 claims abstract description 11
- 229960002747 betacarotene Drugs 0.000 claims abstract description 11
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 9
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 9
- 239000011719 vitamin A Substances 0.000 claims abstract description 9
- 229940045997 vitamin a Drugs 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 abstract description 28
- 239000001301 oxygen Substances 0.000 abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 abstract description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 17
- 230000004888 barrier function Effects 0.000 abstract description 15
- 210000002175 goblet cell Anatomy 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 102000001621 Mucoproteins Human genes 0.000 abstract description 7
- 108010093825 Mucoproteins Proteins 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 4
- 230000036770 blood supply Effects 0.000 abstract description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 235000004400 serine Nutrition 0.000 abstract 2
- 235000008521 threonine Nutrition 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 1
- 230000000881 depressing effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 101150063569 slgA gene Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 241000269800 Percidae Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- -1 monoclonal antibody Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a formula for treating inflammatory bowel disease, and belongs to the field of drugs. The formula consists of ginseng, threonine, serine, cysteine, vitamin C, vitamin E, vitamin A and beta-carotene. The ginseng has functions of enhancing blood supply and oxygen supply of a human body; the threonine, the serine and the cysteine are main constituent parts of mucoprotein; and the vitamin C, the vitamin E, the vitamin A and the beta-carotene have functions of depressing the activity of oxygen radical, eliminating the oxygen radical and protecting body cells. The formula of the invention can provide nutrition, oxygen and raw materials for the generation, renewal and repair of goblet cells and for the secretion of the mucoprotein from the goblet cells to form an intestinal surface mucous layer barrier. The formula of the invention, as an effective formula for treating inflammatory bowel disease, takes significant effects on terminating inflammation, repairing intestinal structure and building the normal intestinal surface mucous layer barrier of the human body.
Description
Technical field
The present invention relates to the combination formula of the treatment Chinese crude drug of inflammatory bowel and aminoacid, vitamin, belong to medicine field.
Background technology
Inflammatory bowel (inflammatoryboweldisease, IBD) is the disease that a kind of pathogenic factor and pathogenesis are not yet completely clear and definite.Because pathogenic factor and pathogenesis are illustrated not yet completely, old friends can not fundamentally stop or delay the progress of this disease course.
Medical Immunology is thought, immune system occurs abnormal to antigen recognition and tolerance, namely normally perches the improper identification of microorganism to intestinal and produces immunne response, cause this disease.Histology and Embryology is then thought, intestinal permeability is too high, causes a large amount of Intestinal Antigens to enter intestinal tissue, has caused the permanent responsing reaction of immune system and has caused this disease.
At present the treatment of inflammatory bowel is taken as the leading factor with Medical Immunology, primary treatment measure be intervene, Immunosuppression response and inflammation to the damage of intestinal, as used glucocorticoid, aminosalicyclic acid supplement, monoclonal antibody, immunosuppressant etc.Above-mentioned remedy measures effect is undesirable and side effect large, so, to the research of the inflammatory bowel cause of disease, find pathogenic factor, take corresponding remedy measures to be the instant task of medical circle.
Summary of the invention
The present invention is based on modern medicine, the basis probing into inflammatory bowel pathogenic factor proposes the remedy measures of oneself, namely intestinal tissue and epithelial goblet cell is reinforced, build normal intestinal tract surface slime layer barrier, stop Intestinal Antigens close, contact, adhere to and enter intestinal tissue, thus block the generation of abnormal immune response, stop the intestinal tissue of inflammation, repairing damage simultaneously.
If carrying out intervention to the immunne response occurred and inflammation is try to stop water from boiling by skimming it off and pouring it back, and prescription therapeutic measure so of the present invention is removing burning wood away under the boiler.
First the gut muco-membranous barrier of human body is intestinal tract surface slime layer barrier, and intestinal tract surface slime layer barrier is the first line of defence of gut muco-membranous barrier.What intestinal tract surface slime layer was secreted by gut epithelium goblet cell mucoproteinly forms.The function of normal intestinal tract surface slime layer be stop the microorganism in intestinal comprise pathogenic microorganism, normally perch microorganism close with food source property antigen, contact, adhere to and enter gut epithelium and intestinal walls, and " attempt " is passed through to microorganism particularly pathogenic microorganism performance adhesion and the effect of parcel of surperficial slime layer, avoid the generation of abnormal immune response and inflammation.
Intestinal slime layer barrier has certain fluctuation, causes a small amount of microbes antigen or food source property antigen to pass through intestinal tract surface slime layer, close, contact, adhere to and enter gut epithelium.These antigens passing through intestinal tract surface slime layer first identify by the pattern recognition receptors of inherent immunity system (PRRs) and cause innate immune response to remove antigen.
When innate immune response can not remove antigen, antigen can by antigen presenting cell (APC) as macrophage (Μ φ), dendritic cell (DC) etc. be absorbed, are offered and cause adaptive immune response.Adaptive immune response enters immune system in the Process of Antigen of intestinal tissue in removing can discharge a large amount of secretory immunoglobulin As (secretorylffA, slgA) to enteric cavity.Can be combined with antigen specifically after slgA releases people's enteric cavity, suppress or kill bacteria, neutralization virus, prevent antigen close, contact, adhere to and enter enteric epithelium, thus reach immunologic balance.
The imbalance of intestinal tract surface slime layer barrier cause Intestinal Antigens in a large number close, contact, adhere to and enter intestinal wall, immune system cannot remove antigen in time, thus immunologic balance is broken, exception throw immunne response and inflammation, damage intestinal tissue, this is the pathogenic factor of inflammatory bowel.
The reason of intestinal tract surface slime layer barrier imbalance may be the performance of goblet cell abnormal condition, comprises the defect of goblet cell, deficiency and renewal, dysfunction; Also may be that goblet cell secretes mucoprotein obstacle.The main cause that goblet cell abnormal condition and goblet cell secrete mucoprotein obstacle is that intestinal blood supply supplies hypoxgia or and has proteinacious malnutrition to cause intestinal cell metabolism substrate deficiency, synthesize mucoprotein insufficient raw material etc.
Content of the present invention is the cooperation prescription that Chinese crude drug people participates in threonine, serine, cysteine, injection Vitamin B_6, A and beta-carotene.
Radix Ginseng has the effect strengthening blood of human body supply and oxygen supply.
The oxygen reserves of human body is relative to very pettiness nutrient deposit, and may cause damage because oxygen supply is not enough to human body when human body has excess oxygen consumption demand, old friend's body increases oxygen supply when morbid state particularly important.
Threonine, serine, cysteine are that goblet cell secretes mucoprotein primary raw material.
Application the present inventor participates in threonine, serine, the prescription of cysteine, intestinal tissue blood supply and oxygen supply can be strengthened, for the generation of goblet cell, repair, upgrade and normal work nutrition and oxygen that abundance is provided, furnish ample material and oxygen for goblet cell secretion is mucoprotein, thus build normal intestinal tract surface slime layer barrier, stop Intestinal Antigens close, contact, adhere to and enter into intestinal tissue, stop the generation of abnormal immune response, and then reach the termination of inflammation and the reparation of intestinal tissue, the mechanism of action of Here it is prescription therapeutic inflammatory bowel of the present invention.
Pathologic data shows, Leukocyte Killing, degraded pathogen, antigen, fragment of tissue need to consume than the oxygen of many 2 ~ 20 times time normal, so the oxygen supply that inflammatory bowel patient strengthens inflammation part is extremely important to the efficiency of inflammation and the termination of inflammation.
Human body can produce a large amount of oxygen-derived free radicals under inflammatory conditions, and oxygen-derived free radicals can cause damage to body, affects the termination of inflammation and the reparation of tissue.
The present invention's application Radix Ginseng can strengthen the oxygen supply of intestinal tissue, thus accelerates the removing of antigen in intestinal tissue, accelerates the generation of intestinal tissue cell, reparation, renewal process, also can produce more oxygen-derived free radicals simultaneously.Injection Vitamin B_6, A and beta-carotene have the effect preventing oxygen-derived free radicals activity, scavenging activated oxygen, protection human body cell, thus inflammatory bowel patient while taking Radix Ginseng, supplement the reparation of these vitamin to the termination of enteritis and tissue especially necessary.
Radix Ginseng of the present invention is the Radix Ginseng that the Pharmacopoeia of the People's Republic of China specifies, in detailed description of the invention, Radix Ginseng consumption measures with dry root and rhizome.
Formula of the present invention can be made into masticatory, containing agent and oral agents, with masticatory, best containing agent effect.
According to mucosal immune system (mucosalimmunesystem), the mucosa traversal system (mucosalmigrationsystem of Medical Immunology, MMS) and " immunity is patrolled and examined " theoretical, the imbalance of intestinal tract surface slime layer barrier can also cause the diseases such as such as periphery arthritis, erythema nodosum, Pyoderma gangrenosum, episcleritis, recurrent oral ulceration; The imbalance of intestinal tract surface slime layer barrier also may cause autoimmune disease, rheumatism and anaphylactic disease.The important research field that the relation of probing into intestinal tract surface slime layer barrier and disease will be 21 century preclinical medicine.Build normal intestinal tract surface slime layer barrier, the intestinal tissue of repairing damage is important content of the present invention, is the primary efficacy of formula of the present invention.
A large amount of facts have proved, applies prescription therapeutic irritable bowel syndrome of the present invention, infectious diarrhea, the long-term diarrhea of unknown cause, asthma, allergic rhinitis have reliable effect.
According to the theory of the combination of Chinese and Western medicine, the disease of human body comes from deficiency of vital energy blood deficiency mostly, and formula of the present invention can strengthen blood supply and the oxygen supply of human body integral, so have good therapeutical effect to the people of deficiency of vital energy blood deficiency.
Reinforce according to healthy and beautiful longevity and says, disease, the aging of human body are mostly relevant with body hypoxic-ischemic, solution body hypoxic-ischemic problem, and most of disease can prevention and therapy, and human longevity can significantly extend.
Detailed description of the invention
One, Radix Ginseng 0.3 gram, threonine 0.5 gram, serine 0.6 gram, cysteine 0.06 gram, vitamin C 50 milligrams, vitamin E 4 milligrams, vitamin A 0.1 milligram, beta-carotene 0.6 milligram are made into masticatory, every day 2 to 4 times.
Two, Radix Ginseng 0.15 gram, threonine 0.25 gram, serine 0.3 gram, cysteine 0.03 gram, Catergen 5 milligrams, vitamin E2 milligram, vitamin A 0.05 milligram, beta-carotene 0.3 milligram are made into masticatory, every day 2 to 4 times.
Three, Radix Ginseng 0.3 gram, threonine 0.5 gram, serine 0.6 gram, cysteine 0.06 gram, vitamin C 50 milligrams, vitamin E 4 milligrams, vitamin A 0.1 milligram, beta-carotene 0.6 milligram are made into containing agent, every day 2 to 4 times.
Four, Radix Ginseng 0.15 gram, threonine 0.25 gram, serine 0.3 gram, cysteine 0.03 gram, Catergen 5 milligrams, vitamin E2 milligram, vitamin A 0.05 milligram, beta-carotene 0.3 milligram are made into containing agent, every day 2 to 4 times.
Five, Radix Ginseng 1 gram, threonine 0.5 gram, serine 0.6 gram, cysteine 0.06 gram, vitamin C 50 milligrams, vitamin E 4 milligrams, vitamin A 0.1 milligram, beta-carotene 0.6 milligram are made into oral agents, every day 2 to 4 times.
Six, Radix Ginseng 0.5 gram, threonine 0.25 gram, serine 0.3 gram, cysteine 0.03 gram, Catergen 5 milligrams, vitamin E2 milligram, vitamin A 0.05 milligram, beta-carotene 0.3 milligram are made into oral agents, every day 2 to 4 times.
Claims (1)
1. treat a prescription for inflammatory bowel, its prescription is characterized as: Radix Ginseng 3 ~ 10 parts, threonine 5 parts, serine 6 parts, cysteine 0.6 part, vitamin C 0.5 part, vitamin E 0.04 part, vitamin A 0.001 part, beta-carotene 0.006 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937154.8A CN105456319A (en) | 2015-12-16 | 2015-12-16 | Formula for treating inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937154.8A CN105456319A (en) | 2015-12-16 | 2015-12-16 | Formula for treating inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456319A true CN105456319A (en) | 2016-04-06 |
Family
ID=55594781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510937154.8A Pending CN105456319A (en) | 2015-12-16 | 2015-12-16 | Formula for treating inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456319A (en) |
-
2015
- 2015-12-16 CN CN201510937154.8A patent/CN105456319A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 中华医学会: "维生素矿物质补充剂在炎症性肠病防治中的临床应用：专家共识", 《中华临床营养杂志》 * |
| 孙菁: "炎症性肠病中的黏膜愈合："营养支持"有无一席之地？", 《宝宝知道HTTPS://BAOBAO.BAIDU.COM/ARTICLE/6D524C3EB17B4DC419FD5BF8DD6D0B38.HTML?LZ=1》 * |
| 祝芳等: "人参皂苷在炎症性肠病中的作用", 《世界华人消化杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105362338A (en) | Composition for treating inflammatory bowel disease | |
| CN105362306A (en) | Composition for treating inflammatory bowel disease | |
| CN105434524A (en) | Composition for treating inflammatory bowel disease | |
| CN105412157A (en) | Composition for treating inflammatory bowel disease | |
| CN105412237A (en) | Composition for treating inflammatory bowel disease | |
| CN105343172A (en) | Prescription for treating inflammatory bowel disease | |
| CN105456319A (en) | Formula for treating inflammatory bowel disease | |
| CN105412233A (en) | Composition for treating inflammatory bowel disease | |
| CN105412190A (en) | Composition for treating inflammatory bowel disease | |
| CN105456356A (en) | Combined formula for treating inflammatory bowel disease | |
| CN105412166A (en) | Composition for treating inflammatory bowel disease | |
| CN105412234A (en) | Composition for treating inflammatory bowel disease | |
| CN105434497A (en) | Composition for treating inflammatory bowel disease | |
| CN105456355A (en) | Formula for treating inflammatory bowel disease | |
| CN105343136A (en) | Prescription for treating inflammatory bowel disease | |
| CN105412163A (en) | Composition for treating inflammatory bowel disease | |
| CN105456318A (en) | Composition for treating inflammatory bowel diseases | |
| CN105412159A (en) | Composition for treating inflammatory bowel disease | |
| CN105395605A (en) | Eleventh formula for treating inflammatory bowel disease | |
| CN105477060A (en) | Prescription for treating inflammatory bowel disease | |
| CN105477062A (en) | Composition for treating inflammatory bowel diseases | |
| CN105477063A (en) | Combined formulation for treating inflammatory bowel diseases | |
| CN105412242A (en) | Composition for treating inflammatory bowel disease | |
| CN105477061A (en) | Combined formulation for treating inflammatory bowel diseases | |
| CN105362305A (en) | Composition for treating inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160406 |